Welcome!

News Feed Item

New Survey Results from The Psoriasis Association Reveal that Significant Improvements Are Still Needed in the Care of Psoriasis Patients to Meet New NICE Recommendations

NORTHAMPTON, England, November 8, 2012 /PRNewswire/ --

New results from a recent survey by The Psoriasis Association reveal that despite progress in the number of patients having their psoriasis severity level assessed, there is still a high level of patient dissatisfaction with treatment, suggesting that these assessments may not be translated into therapy changes where appropriate. Despite an increase in awareness of psoriasis severity measurement, this latest survey also showed that more than half of patients were very dissatisfied with the treatment they were receiving, and over two thirds stated that their doctor or nurse had not discussed any treatment to help improve their quality of life (QoL).[1]

The 'Know your PASI' follow-up survey, which was supported by Janssen, has revealed that patient awareness of Psoriasis Area and Severity Index (PASI) assessments has increased since the first survey in 2011. In fact, the percentage of patients aware of the PASI measurement has nearly trebled to 59%. It is surprising, however, that only 32% of patients have had this important disease severity measurement taken by their doctor. In addition, 63% of patients could not recall their psoriasis severity being measured by any other means, suggesting that they may not be managed effectively as a result.[2]

Helen McAteer, Chief Executive of The Psoriasis Association, says "The survey findings are astonishing and highlight that there has become a need for patients to be proactive in order to drive a change in therapy where they feel they are not receiving the best treatment. We strongly support the need for this change because we see that psoriasis severity assessments are not consistently used or translated into changes in treatment where appropriate."

These findings show a significant disparity between the recommendations being made in the latest National Institute for Health and Clinical Excellence (NICE) guidelines - that all patients should have their disease severity regularly assessed through PASI measurements, and their QoL assessed through the Dermatology Life Quality Index (DLQI), to ensure that they receive the care and treatment they require.[3]Further new findings from the 'Know your PASI' follow-up survey revealed that patients are not being assessed for other key factors such as their cardiovascular risk, which worryingly may mean other conditions and adverse effects of treatment are not being identified.

The government has recognised in a recent framework of care that enhancing QoL for people with long-term conditions is of great importance when considering patient management.[4] The British Association of Dermatologists (BAD) recommends that everyone with psoriasis should have the severity of their disease assessed - taking into consideration where on the body it appears, how widespread it is and the thickness and redness of the plaques. The PASI assessment helps patients and doctors understand the physical severity of the psoriasis and provides a benchmark which, with on-going checks, shows what improvements treatment is making, or crucially, if the treatment is not having the required effect.

Helen McAteer concludes "Based on the new survey findings, The Psoriasis Association is calling for improved awareness of the importance of disease severity, and consequently increased measurement of this in psoriasis patients. We also recommend that to facilitate improved QoL, patients need to proactively request information on different treatments they may eligible for, as soon as their psoriasis severity is deemed great enough for a change in therapy. Patients should feel comfortable speaking up when they are unhappy with their current treatment."

Every person who is passionate about the care provided for patients with psoriasis in the UK is encouraged to sign the Psoriasis Mandate, an online petition calling for improved standards of care in the diagnosis and management of psoriasis. The Psoriasis Association invites signatures to this Mandate, which can be accessed via http://www.psoriasis360.com/psoriasis-mandate to call for support for five key rights of people with psoriasis:

  • Early and accurate diagnosis
  • Access to a specialist for regular treatment review
  • Access to effective treatment options
  • Involvement and choice in a treatment plan with defined goals
  • Understanding and support from society to live a normal life

Estimated to affect up to 1.8 million people in the UK, psoriasis is a painful and debilitating condition characterised by red, raised and inflamed patches on the skin and is classified as being mild, moderate or severe.[5] As well as being physically debilitating, psoriasis can have a deep psychological impact.[6]

Notes to Editors

This press release was funded by Janssen.

About the Psoriasis Area and Severity Index (PASI)

The PASI is a free and simple, painless assessment which takes into account how bad a patient's psoriasis plaques are[7] (how thick, red or sore they are) and how much of the body is affected, to come up with a score. The score is given as a number from 0 (not affected at all) to 72 (very severely affected). If the PASI score is more than 10, the disease is classified as moderate to severe.

Psoriasis is much more than a physical disease and can be considered severe if it has a profound psychological effect on a person's quality of life.  The DLQI is recommended to assess the impact of psoriasis on quality of life.

An interactive PASI calculator (available as an iPhone/iPad app or PC tool) for calculating a PASI score can be downloaded at: http://www.psoriasis360.com/about-psoriasis/types.

About The Psoriasis Association

The Psoriasis Association is the leading national membership organisation for people affected by psoriasis - patients, families, carers and health professionals. Founded in 1968 by Dr Dick Coles, a Consultant Dermatologist in Northampton, the Association has three main aims:

1. To support people who have psoriasis
2. To raise awareness about psoriasis

3. To fund research into the causes, treatments and care of psoriasis

About the Survey

The Know Your PASI Survey is part of a joint collaboration between The Psoriasis Association and Janssen to help educate patients and doctors about how the medical severity of psoriasis is assessed.  The survey was conducted by medeConnect Healthcare Insight, part of the Doctors.net.uk group.

  • Fieldwork for the study was conducted from 4-26 April 2012 with a 5 minute online quantitative survey with 200 psoriasis patients that had participated in the original survey, which took place during 13 July-26 September 2011 and involved 667 respondents, 603 of whom live in the UK, who answered a 5 minute online quantitative survey
  • Recruitment occurred via Psoriasis 360 website and The Psoriasis Association  

About Janssen

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines and metabolic diseases.  Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world.  The legal entity of Janssen in the UK and Ireland is Janssen-Cilag Limited.  Please visit http://www.janssen.co.uk for more information.

References:

  1. The Know Your PASI Follow-Up Survey. Data on file. October 2012
  2. The Know Your PASI Survey. Data on file. October 2011
  3. National Institute for Clinical Excellence. Psoriasis. Assessment and management of psoriasis. Clinical Guideline: methods, evidence and recommendations. October 2012
  4. The NHS Outcomes Framework 2012/13. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_131723.pdf . Last accessed October 2012
  5. The Psoriasis Association. Available at: http://www.psoriasis-association.org.uk. Accessed 22 October 2012
  6. Dubertret L et al. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. British Journal of Dermatology 2006:155:729-36
  7. Mrowietz U et al.  Definition of treatment goals for moderate to severe psoriasis: A European consensus. Archives of Dermatological Research 2011;303:1-10
  8. US National Psoriasis Foundation. Available at http://www.psoriasis.org/about-psoriasis/treatments/severity. Accessed on 22 October 2012.


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists discussed...
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...
Many organizations adopt DevOps to reduce cycle times and deliver software faster; some take on DevOps to drive higher quality and better end-user experience; others look to DevOps for a clearer line-of-sight to customers to drive better business impacts. In truth, these three foundations go together. In this power panel at @DevOpsSummit 21st Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, industry experts will discuss how leading organizations build application success from all...
SYS-CON Events announced today that SIGMA Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. uLaser flow inspection device from the Japanese top share to Global Standard! Then, make the best use of data to flip to next page. For more information, visit http://www.sigma-k.co.jp/en/.
SYS-CON Events announced today that Daiya Industry will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Daiya Industry specializes in orthotic support systems and assistive devices with pneumatic artificial muscles in order to contribute to an extended healthy life expectancy. For more information, please visit https://www.daiyak...
The last two years has seen discussions about cloud computing evolve from the public / private / hybrid split to the reality that most enterprises will be creating a complex, multi-cloud strategy. Companies are wary of committing all of their resources to a single cloud, and instead are choosing to spread the risk – and the benefits – of cloud computing across multiple providers and internal infrastructures, as they follow their business needs. Will this approach be successful? How large is the ...
Your clients expect transactions to never fail, cloud access to be fast and always on, and their data to be protected - no exceptions. Hear about how Secure Service Container (SSC), an IBM-exclusive open technology, enables secure building and hosting of next-generation applications, both cloud and on-premises. SSC protects the full stack from external and insider threats, allows automatic encryption of data in-flight and at-rest, and is tamper-resistant during installation and runtime – with no...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp em...
SYS-CON Events announced today that Interface Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Interface Corporation is a company developing, manufacturing and marketing high quality and wide variety of industrial computers and interface modules such as PCIs and PCI express. For more information, visit http://www.i...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that Mobile Create USA will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Mobile Create USA Inc. is an MVNO-based business model that uses portable communication devices and cellular-based infrastructure in the development, sales, operation and mobile communications systems incorporating GPS capabi...
SYS-CON Events announced today that Nihon Micron will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Nihon Micron Co., Ltd. strives for technological innovation to establish high-density, high-precision processing technology for providing printed circuit board and metal mount RFID tags used for communication devices. For more inf...